The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / EULAR 2015: Anti-Inflammatory Drugs with Dual Targets

EULAR 2015: Anti-Inflammatory Drugs with Dual Targets

September 15, 2015 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Advances in bioengineering are making it possible to develop therapies with molecules that can bind to more than one target.

Advances in bioengineering are making it possible to develop therapies with molecules that can bind to more than one target.

Antibody-like molecules that can bind to more than one target—with the goal of having a more powerful effect than if those targets were treated separately in a combination of therapies—could become part of treatment regimens in rheumatic diseases over the next several years, an expert said here in a session at EULAR 2015, the annual congress of the European League Against Rheumatism (EULAR).

You Might Also Like
  • FDA Issues Stronger Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Warning
  • EULAR 2013: Researchers Expand Targets for PsA, OA Therapy
  • EULAR 2015: Role of ACPA Positivity in Osteoarthritis
Explore This Issue
September 2015
Also By This Author
  • Dermatology & Immunology: Skin Issues Can Present Challenges

Advances in the bioengineering of these molecules, now most commonly seen in cancer treatment, have made development of potential therapies more feasible, with several companies now developing drugs that might be able to be applied in such diseases as pulmonary fibrosis, psoriatic arthritis and osteoarthritis, said Mark Throsby, PhD, chief scientific officer at Merus Biopharmaceuticals, based in The Netherlands.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“These are becoming easier to make in the therapeutic or drug-like setting,” Dr. Throsby said. “There are many companies now that have the tools to really bring these forward.”

In Development

Rather than aiming at one target and the biology surrounding that target, bispecific antibodies offer the possibility of combining two different targets and getting novel modes of action.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Merus’ Biclonics are bispecific, full-length human IgG antibodies developed for use in cancer immunotherapy. Bispecifics have been developed to block two checkpoint inhibitors at once; to block one checkpoint inhibitor and provide a co-stimulatory signal, in a “release the brakes and push on the accelerator” approach; and to target an overexpressed signaling receptor and an immunomodulatory pathway, Dr. Throsby said.

AbbVie and Sanofi are in Phase 2 clinical trials with several bispecific antibodies—for example, one that blocks TNF and IL-17, another that blocks IL-1 alpha and IL-1 beta, and one that blocks IL-4 and IL-13. Dr. Throsby said it will be interesting to see how the body reacts to these therapies, because they are different from naturally occurring IgG antibodies.

“I think one of the key things to look for would be immunogenicity, because this is not looking exactly like an IgG, and immunogenicity is very difficult to tease out in preclinical studies,” Dr. Throsby said.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Macrogenics and Takeda have teamed up on the development of a bispecific antibody targeting CD32B and CD79B for a B cell-targeted therapy that doesn’t lead to B cell depletion. This is being studied for potential use in RA and systemic lupus erythematosus, and is also in Phase 2.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Meeting Reports, Osteoarthritis, Soft Tissue Pain Tagged With: Drugs, Osteoarthritis, Psoriatic Arthritis, pulmonary fibrosis, TreatmentIssue: September 2015

You Might Also Like:
  • FDA Issues Stronger Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Warning
  • EULAR 2013: Researchers Expand Targets for PsA, OA Therapy
  • EULAR 2015: Role of ACPA Positivity in Osteoarthritis
  • Anti-TNF-Associated Skin Lesions Common in Inflammatory Bowel Disease

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)